Showing results (151-160 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trialSara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.
The Lancet. Haematology|May 30, 2025
Machine-learning models to predict iron recovery after blood donation: a model development and external validation studyWanjin Li, Chen-Yang Su, Amber Meulenbeld, et al.
The Lancet. Haematology|October 19, 2025
IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 studyQianwen Xu, Yugang Guo, Min Gao, et al.
The Lancet. Haematology|February 15, 2026
Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 studyTanja A Gruber, Sima Jeha, Rebecca J Deyell, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
The Lancet. Haematology|March 16, 2025
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 studyAjai Chari, Cyrille Touzeau, Carolina Schinke, et al.
The Lancet. Haematology|April 30, 2025
Management of iron deficiency in children, adults, and pregnant individuals: evidence-based and expert consensus recommendationsAshley E Benson, Jamie O Lo, Maureen O Achebe, et al.
The Lancet. Haematology|March 14, 2026
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trialDominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, et al.
The Lancet. Haematology|March 13, 2026
Building safeguards for gene therapy in haemophiliaKelsey Uminski, Christine A Lee, Cedric Hermans
The Lancet. Haematology|March 30, 2024
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trialXiao-Peng Tian, Jun Cai, Yi Xia, et al.
Pageof 73